1 <u>Supplementary Materials</u>

2 The "vaccinatable" population and doses requiring a decision

- 3 Assume that we have D vaccine doses for deployment. In order to consider our question of
- 4 deploying vaccine doses as first or second doses we only wish to model the impact of those
- 5 fraction of the doses that we actually have a choice to deploy as second doses. I.e. if k
- 6 individuals have received a first dose, and have not yet been infected, and k < D, then only k
- 7 of our total doses *D* require a decision of deploying as a first or second dose. On the other
- 8 hand, if $k \ge D$, then we can choose to deploy all of our doses as second doses. Thus, we only
- 9 consider the doses of vaccine for which a deployment decision is required, (we call this
- 10 quantity $d = \min(k, D)$).
- 11 Therefore, for the vaccine doses, d we can either deploy them to a group of d people who
- 12 have already received 1 dose (and who we assume have not been infected, call this
- 13 population, $N_1 = d$), or a different group of d people who have not received a first dose (call
- 14 this population, $N_0 = d$). Therefore, we define the "vaccinatable" individuals as these N_1 +
- 15 $N_0 = 2d$ individuals in our total population to whom we could choose to deploy our d
- 16 vaccine doses (either as a first dose or a second dose). We assume that the individuals with 1
- 17 dose already (N_1) received their first dose *s* weeks before the current vaccine deployment
- 18 decision of interest and that *s* is at least 4 weeks (given the MVA-BN vaccine schedule
- 19 recommends a second dose not earlier than 4 weeks after the first).

Generalising the comparison of one and two dose strategies when the force of infection is not constant with time.

- 22 Within our analysis we calculate the expected number of cases that occurs within the
- vaccinatable population (d). This analysis used a constant force of infection to model the case
- numbers and the resulting ratio of cases averted is given by (methods equation 3),

$$RCA(t) = \frac{CA_1(t)}{CA_2(t)} = \frac{\int_0^t VE_1(x)dx + \int_0^t VE_1(x+s)dx}{\int_0^t VE_{2,s}(x)dx}.$$
 (1)

26 This quantity translates to the ratio of the average vaccine effectiveness across a group of

27 people (unvaccinated individuals contribute 0 to average effectiveness).

Applying a more sophisticated model, we can model case numbers when the infection rate

varies with time. That is, consider an unvaccinated susceptible population, S_u , with a varying

30 rate of exposure over time. The number of susceptible unvaccinated individuals over time, t,

31 is described by,

$$\frac{dS_u}{dt} = -r(t)S_u,\tag{2}$$

32

25

- 33 where r(t) is the infection rate at time, t. Here we ignore effects of individuals becoming
- 34 susceptible again (i.e. we assume infected individuals acquire a high level of immunity for
- 35 the duration of our analysis). Similarly, for a susceptible vaccinated population, S_v , we
- 36 describe this rate of infection being reduced by one minus the vaccine effectiveness (VE),
- and so the number of vaccinated, susceptible individuals is described by,

$$\frac{dS_v}{dt} = -(1 - VE(t))r(t)S_v.$$
(3)

38

Solving, equations (2) and (3) we find that the number of unvaccinated and vaccinated susceptible individuals at a time t are given by,

$$S_u(t) = S_u(0)e^{-\int_0^t r(\lambda)d\lambda}$$
⁽⁴⁾

41 and

$$S_{\nu}(t) = S_{\nu}(0)e^{-\int_{0}^{t}r(\lambda)(1-VE(\lambda))\,d\lambda} = S_{\nu}(0)e^{-\int_{0}^{t}r(\lambda)d\lambda}e^{\int_{0}^{t}r(\lambda)VE(\lambda)\,d\lambda}$$
(5)

42 respectively.

43 Therefore, the total number of cases that have occurred between time t = 0 and time t in the 44 unvaccinated and vaccinated populations are given by,

$$I_u(t) = S_u(0) - S_u(0)e^{-\int_0^t r(\lambda)d\lambda}$$
⁽⁶⁾

45 and

$$I_{\nu}(t) = S_{\nu}(0) - S_{\nu}(0)e^{-\int_{0}^{t} r(\lambda)d\lambda}e^{\int_{0}^{t} r(\lambda)VE(\lambda)\,d\lambda}$$
(7)

46 respectively.

47 The deployment strategies

48 We now consider three scenarios

- 49 i. Baseline reference scenario
- 50 First, as a reference, we consider a scenario of a naïve population. Under this scenario a
- 51 group of 2*d* naïve individuals are exposed to the force of infection r(t). Thus, from equation
- 52 (6) above, and noting that in our case we have $S_u(0) = S_v(0) = 2d$, the total number of
- 53 cases by time t is given by,

$$I_{base}(t) = 2d\left(1 - e^{-\int_0^t r(\lambda)d\lambda}\right)$$
(8)

54 ii. Two dose scenario

55 Under this scenario, the doses *d* are deployed to the group N_1 as second doses. This provides 56 these individuals with the VE of two doses, but provides individuals in the group N_0 with no 57 protection. The second dose is administered at the time of the decision point t = 0 and the 58 vaccine effectiveness of this group is given by $VE_{2,s}(t)$, where *s* is the space between the first 59 and second dose (since VE is influenced by dose spacing). Thus, from equations (6) and (7) 50 the total number of cases that will occur by time *t* under this scenario is given by,

$$I_{2dose}(t) = d\left(2 - e^{-\int_0^t r(\lambda)d\lambda} - e^{-\int_0^t r(\lambda)(1 - VE_{2,s}(\lambda))\,d\lambda}\right)$$
(9)

61 The number of cases averted in the two dose scenario can be calculated by comparing the

62 total number of cases under this scenario with the number of cases under the baseline

63 scenario. Therefore the number of cases averted under the two dose scenario, $CA_2(t)$, is given 64 by:

$$CA_{2}(t) = I_{base}(t) - I_{2dose}(t) = d\left(e^{-\int_{0}^{t} r(\lambda)(1 - VE_{2,s}(\lambda)) d\lambda} - e^{-\int_{0}^{t} r(\lambda) d\lambda}\right)$$
(10)

65

66 iii. One dose scenario

Finally, we consider the scenario where the d doses are deployed as first doses to the N_0

68 group. This leaves the N_1 group with the waning protection of their first dose given s + t69 earlier. From equation (7) it follows that the total number of cases by time t under this 70 scenario is given by,

70 sechario is given by,

$$I_{1dose}(t) = d\left(2 - e^{-\int_0^t r(\lambda)(1 - VE_1(\lambda)) d\lambda} - e^{-\int_0^t r(\lambda)(1 - VE_1(\lambda + s)) d\lambda}\right)$$
(11)

71

72 The number of cases averted in the one dose scenario can be calculated by comparing the

total number of cases under this scenario with the number of cases under the baseline

scenario. Therefore the number of cases averted under the one dose scenario, $CA_1(t)$, is given by:

$$CA_{1}(t) = I_{base}(t) - I_{1dose}(t)$$

$$= d \left(e^{-\int_{0}^{t} r(\lambda)(1 - VE_{1}(\lambda)) d\lambda} + e^{-\int_{0}^{t} r(\lambda)(1 - VE_{1}(\lambda + s)) d\lambda} - 2e^{-\int_{0}^{t} r(\lambda) d\lambda} \right).$$
(12)

76

Under the above scenarios we have calculated the cases averted using either the one or two 77 dose vaccination strategy. To simplify these relationships further, we now make first order 78 approximation of the exponential terms in equations (10) and (12). This first order 79 approximation assumes that the total force of infection over the relevant time interval is small 80 (in an unvaccinated cohort is small – i.e. $\int_0^t r(\lambda) d\lambda \ll 1$, which is akin to an assumption of 81 rare events – of note, since VE is between 0 and 1, it follows that $\int_0^t r(\lambda) VE(\lambda) d\lambda < 0$ 82 $\int_0^t r(\lambda) d\lambda \ll 1$). Under this assumption second order and larger terms in the Taylor 83 expansion of an exponential function, given by, 84

85
$$e^x = 1 + x + \frac{x^2}{2!} + \frac{x^3}{3!} + \cdots$$

86 will be very small and thus, we assume,

87
$$e^{-\int_0^t r(\lambda)(1-VE_{2,s}(\lambda))d\lambda} \approx 1 - \int_0^t r(\lambda) \left(1 - VE_{2,s}(\lambda)\right) d\lambda$$

88
$$e^{-\int_0^t r(\lambda)VE_1(\lambda+s)\,d\lambda} \approx 1 - \int_0^t r(\lambda)(1 - VE_1(\lambda+s))\,d\lambda$$

89

$$e^{-\int_0^t r(\lambda) V E_1(\lambda) \, d\lambda} \approx 1 - \int_0^t r(\lambda) (1 - V E_1(\lambda)) \, d\lambda$$

90 and

91
$$e^{-\int_0^t r(\lambda) \, d\lambda} \approx 1 - \int_0^t r(\lambda) d\lambda.$$

92 Substituting these approximations into equations (10) and (12) gives,

$$CA_{2}(t) = d\left(\int_{0}^{t} r(\lambda) \left(VE_{2,s}(\lambda)\right) d\lambda\right)$$
⁽¹³⁾

93

94 and

$$CA_{1}(t) = d\left(\int_{0}^{t} r(\lambda) \left(VE_{1}(\lambda+s)\right) d\lambda + \int_{0}^{t} r(\lambda) \left(VE_{1}(\lambda)\right) d\lambda\right).$$
(14)

95

96 It is clear from the above that the ratio of cases averted (equations 13 and 14) will not be

97 independent of the force of infection, as was the case when the force of infection was

constant (main text). However, instead we can look at the difference in cases averted in thesetwo cases,

$$CA_{1}(t) - CA_{2}(t)$$

$$= d\left(\int_{0}^{t} r(\lambda) \left(VE_{1}(\lambda + s)\right) d\lambda + \int_{0}^{t} r(\lambda) \left(VE_{1}(\lambda)\right) d\lambda - \int_{0}^{t} r(\lambda) \left(VE_{2,s}(\lambda)\right) d\lambda\right).$$

$$(15)$$

Therefore, it follows that for the cases averted by the one dose strategy to be greater than thetwo dose strategy we require that,

$$CA_{1}(t) - CA_{2}(t)$$

$$= d\left(\int_{0}^{t} r(\lambda)VE_{1}(\lambda) d\lambda + \int_{0}^{t} r(\lambda)VE_{1}(\lambda + s) d\lambda - \int_{0}^{t} r(\lambda)VE_{2,s}(\lambda) d\lambda\right) > 0$$
(16)

102 and this can only be true when

$$\left(\int_{0}^{t} r(\lambda) V E_{1}(\lambda) \, d\lambda + \int_{0}^{t} r(\lambda) V E_{1}(\lambda + s) \, d\lambda - \int_{0}^{t} r(\lambda) V E_{2,s}(\lambda) \, d\lambda\right) > 0, \tag{17}$$

103

104 since d > 0. Combining these integrals, we see that we require that

$$\left(\int_{0}^{t} r(\lambda) \left(VE_{1}(\lambda) + VE_{1}(\lambda + s) - VE_{2,s}(\lambda) \right) d\lambda \right) > 0.$$
⁽¹⁸⁾

105 We notice that under the strict condition that $VE_1(\lambda) + VE_1(\lambda + s) - VE_{2,s}(\lambda) > 0$ for all 106 $0 < \lambda < t$, equation (18) will hold true. Thus, rearranging this expression, we see that the one 107 dose strategy will avert more cases than the 2 dose strategy if the ratio (which we call the 108 vaccine effectiveness of the vaccinatable population, RVE),

$$RVE(t) = \frac{VE_1(t) + VE_1(t+s)}{VE_{2,s}(t)} > 1,$$
(19)

- 109 at all time-points in our time interval of interest (2 years in the main text).
- 110 In the same way the cases averted by the two dose strategy will be greater than the one dose
- 111 when the ratio RVE(t) < 1 at all time-points.
- 112 Importantly, this ratio is greater than 1 at all time points for the MVA-BN vaccine regimens
- 113 we are considering (figure S1). Therefore, our result that more cases will be averted by
- administering limited vaccine doses as first doses to as many individuals as possible rather
- than as second doses to those already vaccinated in the main text holds independently of
- assumptions of a constant force of infection.





Figure S1: The ratio of vaccine effectiveness at each time point, RVE(t), from equation (19) when the space between doses is, *s*, 4 weeks. Since this ratio is always greater than 1 over the

- when the space between doses is, s, 4 weeks. Since this ratio is always greater than 1 over the 2 year period of interest, it follows (as described above) that a one-dose vaccination strategy
- 121 will avert more cases than a two dose strategy, given limited vaccine supply. Note that the
- same result holds whether the spacing of doses is 6 months or 1 year (not shown).

123

124 Considering a time varying force of infection along with different risks of infection or 125 severe outcomes

126 Finally, we consider the case of a time varying force of infection and two groups with

- 127 different force of infection. We assume the force of infection in the high risk group is given
- 128 by $r_h(t) = r_h h(t)$ and the risk in the low risk group is given by $r_l(t) = r_l h(t)$, where h(t) is
- 129 the time varying component of the force of infection. Under this assumption the relative risk

between the two groups is constant over time, but the absolute force of infection for each

131 group is time varying. Under this assumption we see that,

$$I_{2dose}(t) = d\left(2 - e^{-r_l \int_0^t h(\lambda) d\lambda} - e^{-r_h \int_0^t h(\lambda) d\lambda} e^{r_h \int_0^t h(\lambda) V E_{2,s}(\lambda) d\lambda}\right)$$
(20)

and

$$I_{1dose}(t) = d \left(2 - e^{-r_l \int_0^t h(\lambda) d\lambda} e^{r_l \int_0^t h(\lambda) V E_1(\lambda) d\lambda} - e^{-r_h \int_0^t h(\lambda) d\lambda} e^{r_h \int_0^t h(\lambda) V E_1(\lambda+s) d\lambda} \right)$$
(21)

The difference in cases averted between these two strategies is given by,

$$CA_{1}(t) - CA_{2}(t)$$

$$= d \left(e^{-r_{l} \int_{0}^{t} h(\lambda) d\lambda} + e^{-r_{h} \int_{0}^{t} h(\lambda) d\lambda} e^{r_{h} \int_{0}^{t} h(\lambda) V E_{2,s}(\lambda) d\lambda} - e^{-r_{l} \int_{0}^{t} h(\lambda) d\lambda} e^{r_{l} \int_{0}^{t} h(\lambda) V E_{1}(\lambda) d\lambda} - e^{-r_{h} \int_{0}^{t} h(\lambda) d\lambda} e^{r_{h} \int_{0}^{t} h(\lambda) V E_{1}(\lambda+s) d\lambda} \right)$$

$$(22)$$

Taking a first order approximation, as above, and expanding and simplifying we find that

$$I_{1dose}(t) - I_{2dose}(t)$$

$$\approx d\left(r_l \int_0^t h(\lambda) V E_1(\lambda) \, d\lambda + r_h \int_0^t h(\lambda) V E_1(\lambda + s) \, d\lambda - r_h \int_0^t h(\lambda) V E_{2,s}(\lambda) \, d\lambda\right).$$

$$(23)$$

132

133 Thus, as above $I_{1dose}(t) - I_{2dose}(t) > 0$ only when,

$$\int_{0}^{t} h(\lambda) \left(r_{l} V E_{1}(\lambda) + r_{h} V E_{1}(\lambda + s) - r_{h} V E_{2,s}(\lambda) \right) d\lambda > 0.$$
⁽²⁴⁾

134 Equation (24) will be satisfied whenever

$$r_l V E_1(\lambda) + r_h V E_1(\lambda + s) - r_h V E_{2,s}(\lambda) > 0$$
⁽²⁴⁾

- 135 for all $0 < \lambda < t$.
- 136 Thus, the one dose strategy will avert more cases than the 2 dose strategy whenever,

$$\frac{r_h}{r_l} > \frac{VE_1(t)}{VE_{2,s}(t) - VE_1(t+s)}$$
(25)

for time points in our analysis. From this we see that in the case of a time varying force of 137

infection, we can define a critical relative risk threshold between high risk and low risk 138

individuals, such that when the ratio in equation 25 is satisfied, we can be confident the one 139 dose-strategy is superior. This proof leaves open the possibility that even in some cases

140

where equation (25) is not satisfied, the one-dose strategy may be optimal. 141